Can the androgen receptor blocking become the basis of a new method of treatment of triple negative breast cancer?
https://doi.org/10.18027/2224-5057-2017-1-18-25
Abstract
Triple-negative breast cancer (TNBC) represents approximately 15% –20% of all diagnosed breast cancers. This tumor subtype characterized by the absence of expression of the estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor (HER2) protein. Tumor heterogeneity of triple negative breast cancer is the main barrier in the treatment of this tumor subtype. Although estrogen receptor (ER) and human epidermal growth factor receptor (HER2) are the mainstay therapeutic targets in breast cancer, the androgen receptor (AR) is evolving as a molecular target for cancers that have developed resistance to conventional treatments.
About the Authors
E. K. ZILTSOVA
Research Institute of oncology named after N. N. Petrov
Russian Federation
MD, PhD
Russian Federation
MD, PhD
O. A. IVANOVA
Research Institute of oncology named after N. N. Petrov
Russian Federation
MD, PhD
Russian Federation
MD, PhD
P. V. KRIVOROTKO
Research Institute of oncology named after N. N. Petrov
Russian Federation
MD, PhD, DSc
Russian Federation
MD, PhD, DSc
V. G. IVANOV
Research Institute of oncology named after N. N. Petrov
Russian Federation
MD, PhD
Russian Federation
MD, PhD
E. V. CYRLINA
Research Institute of oncology named after N. N. Petrov
Russian Federation
MD, PhD
Russian Federation
MD, PhD
G. A. DASHYAN
Research Institute of oncology named after N. N. Petrov
Russian Federation
MD, PhD, DSc
Russian Federation
MD, PhD, DSc
T. T. TABAGUA
Research Institute of oncology named after N. N. Petrov
Russian Federation
MD, PhD
Russian Federation
MD, PhD
K. S. NIKOLAEV
Research Institute of oncology named after N. N. Petrov
Russian Federation
MD, PhD
Russian Federation
MD, PhD
L. P. GIGOLAEVA
Research Institute of oncology named after N. N. Petrov
Russian Federation
postgraduate
Russian Federation
postgraduate
V. F. SEMIGLAZOV
Research Institute of oncology named after N. N. Petrov
Russian Federation
MD, PhD, DSc
Russian Federation
MD, PhD, DSc
References
1. DeSantis C., Ma J., Bryan L., Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 2014; 64:52–62.
2. Curtis C., Shah S. P., Chin S. F., Turashvili G., Rueda O. M., Dunning M. J. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486:346–52.
3. Santagata S., Thakkar A., Ergonul A., Wang B., Woo T., Hu R. et al. Taxonomy of breast cancer based on normal cell phenotype predicts outcome. J Clin Invest 2014; 124:859–70.
4. Perou C. M., Sorlie T., Eisen M. B., van de Rijn M., Jeffrey S. S., Rees C. A. et al. Molecular portraits of human breast tumours. Nature 2000; 406:747–52.
5. de Ruijter T. C., Veeck J., de Hoon J. P., van Engeland M., Tjan-Heijnen V. C. Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol 2011; 137:183–92.
6. Bosch A., Eroles P., Zaragoza R., Vina J. R., Lluch A. Triplenegative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 2010; 36:206–15.
7. Dent R., Trudeau M., Pritchard K. I., Hanna W. M., Kahn H. K., Sawka C. A. et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13:4429–34.
8. Metzger-Filho O., Tutt A., de Azambuja E., Saini K. S., Viale G., Loi S. et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 2012; 30:1879–87.
9. Jiao Q., Wu A., Shao G., Peng H., Wang M., Ji S. et al. The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers. J Thorac Dis 2014; 6:1329–35.
10. McNamara K.M., Yoda T., Takagi K., Miki Y., Suzuki T., Sasano H. Androgen receptor in triple negative breast cancer. J Steroid Biochem Mol Biol 2013; 133:66–76.
11. McNamara K.M., Moore N. L., Hickey T. E., Sasano H., Tilley W. D. Complexities of androgen receptor signalling in breast cancer. Endocr Relat Cancer 2014; 21: T161–81.
12. Safarpour D., Pakneshan S., Tavassoli F. A. Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified? Am J Cancer Res 2014; 4:353–68.
13. Crown J., O’Shaughnessy J., Gullo G. Emerging targeted therapies in triple-negative breast cancer. Ann Oncol 2012; 23(Suppl 6): vi56–65.
14. Gao, W. Androgen receptor as a therapeutic target. Adv. Drug.Deliv. Rev. 2010 Oct. – Vol. 62, N13. – P. 1277–1284.
15. Hu Z., Fan C., Oh D. S. et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7:96.
16. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490:61–70.
17. Lehmann B. D., Bauer J. A., Chen X., Sanders M. E., Chakravarthy A. B., Shyr Y. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121:2750–67.
18. Xu H., Eirew P., Mullaly S. C., Aparicio S. The omics of triplenegative breast cancers. Clin Chem 2014; 60:122–33.
19. Perou C. M. Molecular stratification of triple-negative breast cancers. Oncologist 2010; 15(Suppl 5):39–48.
20. Park H. S., Jang M. H., Kim E. J., Kim H. J., Lee H. J., Kim Y. J. et al. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Mod Pathol 2014; 27:1212–22.
21. Baselga J., Gomez P., Greil R., Braga S., Climent M. A.,Wardley A. M. et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol 2013; 31:2586–92.
22. Shah S. P., Roth A., Goya R., Oloumi A., Ha G., Zhao Y. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012; 486:395–9.
23. Banerji S., Cibulskis K., Rangel-Escareno C., Brown K. K., Carter S. L., Frederick A. M. et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012; 486:405–9.
24. Barbie T. U., Alexe G., Aref A. R., Li S., Zhu Z., Zhang X. et al. Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. J Clin Invest 2014; 124:5411–23.
25. Gucalp A., Tolaney S., Isakoff S. J., Ingle J. N., Liu M. C., Carey L. A. et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res 2013; 19:5505–12.
26. Paul A., Gunewardena S., Stecklein S. R., Saha B., Parelkar N., Danley M. et al. PKClambda/iota signaling promotes triplenegative breast cancer growth and metastasis. Cell Death Differ 2014; 21:1469–81.
27. Androgen receptor expression and breast cancer survival in postmenopausal women / R. Hu et al. // Clin. Cancer. Res. – 2011 Apr. – Vol. 17, N7. – P. 1867–1874.
28. Tsang J. Y., Ni Y. B., Chan S. K., Shao M. M., Law B. K., Tan P. H. et al. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers. Ann Surg Oncol 2014; 21:2218–28.
29. Lim E., Ni M., Cao S., Hazra A., Tamimi R. M., Brown M. Importance of breast cancer subtype in the development of androgen receptor directed therapy. Curr Breast Cancer Rep 2014; 6:71–8.
30. Hickey T. E., Robinson J. L., Carroll J. S., Tilley W. D. Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Mol Endocrinol 2012; 26:1252–67.
31. Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype / L. J. McGhan et al. // Ann. Surg. Oncol. – 2014 Feb. – Vol. 21, N2. – P. 361–367.
32. Prognostic markers in triple-negative breast cancer / E. A. Rakha et al. // Cancer. – 2007 Jan. – Vol. 109, N1. – P. 25–32.
33. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray / J. He et al. //Med. Oncol. – 2012 Jun. – Vol. 29, N2. – P. 406–410.
34. Expression of androgen receptors in primary breast cancer / S. Park et al. // Ann. Oncol. – 2010 Mar. – Vol.21, N3. – P. 488– 492.
35. Cuenca-Lopez M.D., Montero J. C., Morales J. C., Prat A., Pandiella A., Ocana A. Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer 2014; 14:302.
36. Lehmann B. D., Bauer J. A., Schafer J. M., Pendleton C. S., Tang L., Johnson K. C. et al. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res 2014; 16:406.
37. Cochrane D. R., Bernales S., Jacobsen B. M., Cittelly D. M., Howe E. N., D’Amato N.C. et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res 2014; 16: R7.
38. Stage 1 results from MDV3100–11: a 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor. In: Advanced AR+ triple-negative breast cancer (TNBC) 37th annual San Antonio breast cancer symposium, 2014.
39. Kwok C. W., Treeck O., Buchholz S., Seitz S., Ortmann O., Engel J. B. Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC). Target Oncol 2014.
40. Rizza P., Barone I., Zito D., Giordano F., Lanzino M., De Amicis F. et al. Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines. Breast Cancer Res 2014; 16: R21.
Review
For citations:
ZILTSOVA E.K., IVANOVA O.A., KRIVOROTKO P.V., IVANOV V.G., CYRLINA E.V., DASHYAN G.A., TABAGUA T.T., NIKOLAEV K.S., GIGOLAEVA L.P., SEMIGLAZOV V.F. Can the androgen receptor blocking become the basis of a new method of treatment of triple negative breast cancer? Malignant tumours. 2017;(1):18-25. (In Russ.) https://doi.org/10.18027/2224-5057-2017-1-18-25
Views:
1720
Email this article 